دورية أكاديمية
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
| العنوان: | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma. |
|---|---|
| المؤلفون: | Chen BB; Department of Medical Imaging, National Taiwan University Hospital, Taipei City, Taiwan.; Department of Radiology, College of Medicine, National Taiwan University, Taipei City, Taiwan., Liang PC; Department of Medical Imaging, National Taiwan University Hospital, Taipei City, Taiwan.; Department of Radiology, College of Medicine, National Taiwan University, Taipei City, Taiwan.; Department of Medical Imaging, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu City, 300, Taiwan., Shih TT; Department of Medical Imaging, National Taiwan University Hospital, Taipei City, Taiwan.; Department of Radiology, College of Medicine, National Taiwan University, Taipei City, Taiwan., Liu TH; Department of Oncology, National Taiwan University Hospital, No 7, Chung-Shan South Rd, Taipei City, 100, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Shen YC; Department of Oncology, National Taiwan University Hospital, No 7, Chung-Shan South Rd, Taipei City, 100, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Lu LC; Department of Oncology, National Taiwan University Hospital, No 7, Chung-Shan South Rd, Taipei City, 100, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Lin ZZ; Department of Oncology, National Taiwan University Hospital, No 7, Chung-Shan South Rd, Taipei City, 100, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Hsu C; Department of Oncology, National Taiwan University Hospital, No 7, Chung-Shan South Rd, Taipei City, 100, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Hsu CH; Department of Oncology, National Taiwan University Hospital, No 7, Chung-Shan South Rd, Taipei City, 100, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Cheng AL; Department of Oncology, National Taiwan University Hospital, No 7, Chung-Shan South Rd, Taipei City, 100, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Shao YY; Department of Oncology, National Taiwan University Hospital, No 7, Chung-Shan South Rd, Taipei City, 100, Taiwan. yuyunshao@gmail.com.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei City, Taiwan. yuyunshao@gmail.com.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. yuyunshao@gmail.com. |
| المصدر: | European radiology [Eur Radiol] 2023 Jan; Vol. 33 (1), pp. 512-522. Date of Electronic Publication: 2022 Jul 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer International Country of Publication: Germany NLM ID: 9114774 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1084 (Electronic) Linking ISSN: 09387994 NLM ISO Abbreviation: Eur Radiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : Springer International, c1991- |
| مواضيع طبية MeSH: | Sarcopenia*/complications , Sarcopenia*/diagnostic imaging , Sarcopenia*/epidemiology , Carcinoma, Hepatocellular*/complications , Carcinoma, Hepatocellular*/therapy , Liver Neoplasms*/complications , Liver Neoplasms*/therapy, Humans ; Retrospective Studies ; Prognosis ; Muscle, Skeletal/pathology ; Obesity/complications ; Obesity/epidemiology ; Obesity/pathology ; Immunotherapy |
| مستخلص: | Objectives: To investigate the association of sarcopenia, myosteatosis, and sarcopenic obesity with survival outcomes among patients who underwent immunotherapy for advanced hepatocellular carcinoma (HCC). Methods: In this retrospective analysis, patients who initiated immunotherapy for advanced HCC were enrolled. Sarcopenia and myosteatosis were evaluated on pretreatment CT at L3 level by skeletal muscle index and mean muscle attenuation using predefined cutoff values. Sarcopenic obesity was defined as concurrent sarcopenia and body mass index > 25 kg/m 2 . The log-rank test and the Cox proportional hazards model were used to compare overall survival (OS) and progression-free survival (PFS). Results: A total of 138 patients was included (discovery cohort n = 111, validation cohort n = 27). In the discovery cohort, patients with sarcopenia exhibited significantly poorer PFS (p = 0.048) and OS (p = 0.002) than patients without sarcopenia. Patients with myosteatosis exhibited significantly poorer PFS (p < 0.001) and OS (p < 0.001) than patients without myosteatosis. Patients with sarcopenic obesity compared to patients without sarcopenic obesity exhibited significantly poorer OS (p = 0.006) but not PFS (p = 0.31). In multivariate analysis adjusting for patient demographics, tumor extent, and liver function reserve, myosteatosis remained an independent predictor of poor PFS (p = 0.014) and OS (p = 0.007); sarcopenia remained an independent predictor for poor OS (p = 0.007). The prediction models for survival outcomes built by the discovery cohort showed similar performance in the validation cohort. Conclusions: Sarcopenia and myosteatosis are independent prognostic factors in patients who received immunotherapy for advanced HCC. Key Points: • Sarcopenia and myosteatosis can be evaluated by CT at L3 level. • Sarcopenia, myosteatosis, and sarcopenic obesity were associated with poor survival outcomes in patients who underwent immunotherapy for advanced HCC. • Myosteatosis was an independent predictor of PFS and OS, and sarcopenia was independent for OS in these patients. (© 2022. The Author(s), under exclusive licence to European Society of Radiology.) |
| References: | Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. (PMID: 10.3322/caac.21660) Shao YY, Wang SY, Lin SM (2021) Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc 120:1051–1060. (PMID: 10.1016/j.jfma.2020.10.031) Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B (2021) Systemic treatment of hepatocellular carcinoma. An EASL position paper. J Hepatol. https://doi.org/10.1016/j.jhep.2021.07.004. Liu TH, Shao YY, Hsu CH (2021) It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade. J Formos Med Assoc 120:1–4. (PMID: 10.1016/j.jfma.2020.07.009) Singh A, Beechinor RJ, Huynh JC et al (2021) Immunotherapy updates in advanced hepatocellular carcinoma. Cancers (Basel) 13. El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502. (PMID: 10.1016/S0140-6736(17)31046-2) Zhu AX, Finn RS, Edeline J et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19:940–952. (PMID: 10.1016/S1470-2045(18)30351-6) Finn RS, Ryoo BY, Merle P et al (2020) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 38:193–202. (PMID: 10.1200/JCO.19.01307) Marasco G, Serenari M, Renzulli M et al (2020) Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. J Gastroenterol 55:927–943. (PMID: 10.1007/s00535-020-01711-w) Wu CH, Liang PC, Hsu CH, Chang FT, Shao YY, Ting-Fang Shih T (2021) Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma. J Formos Med Assoc 120:559–566. (PMID: 10.1016/j.jfma.2020.07.005) Kano M, Hihara J, Tokumoto N et al (2021) Association between skeletal muscle loss and the response to nivolumab immunotherapy in advanced gastric cancer patients. Int J Clin Oncol 26:523–531. (PMID: 10.1007/s10147-020-01833-4) Kim YY, Lee J, Jeong WK et al (2021) Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer 24:457–466. (PMID: 10.1007/s10120-020-01124-x) Nishioka N, Naito T, Notsu A et al (2021) Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. Cancer Med 10:247–256. (PMID: 10.1002/cam4.3631) Bilen MA, Martini DJ, Liu Y et al (2020) Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy. Oncologist 25:e528–e535. (PMID: 10.1634/theoncologist.2019-0751) Takenaka Y, Oya R, Takemoto N, Inohara H (2021) Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. J Cachexia Sarcopenia Muscle. https://doi.org/10.1002/jcsm.12755. Dercle L, Ammari S, Champiat S et al (2016) Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. Eur J Cancer 65:33–42. (PMID: 10.1016/j.ejca.2016.05.031) Batsis JA, Villareal DT (2018) Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 14:513–537. (PMID: 10.1038/s41574-018-0062-9) Young AC, Quach HT, Song H et al (2020) Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma. J Immunother Cancer 8:e000821. (PMID: 10.1136/jitc-2020-000821) Ahn H, Kim DW, Ko Y et al (2021) Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: a new paradigm beyond sarcopenia. Ageing Res Rev 70:101398. (PMID: 10.1016/j.arr.2021.101398) Lee CM, Kang J (2020) Prognostic impact of myosteatosis in patients with colorectal cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 11:1270–1282. (PMID: 10.1002/jcsm.12575) Aleixo GFP, Shachar SS, Nyrop KA, Muss HB, Malpica L, Williams GR (2020) Myosteatosis and prognosis in cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol 145:102839. (PMID: 10.1016/j.critrevonc.2019.102839) Peng YC, Wu CH, Tien YW, Lu TP, Wang YH, Chen BB (2021) Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy. Eur Radiol 31:2472–2481. (PMID: 10.1007/s00330-020-07294-7) Su H, Ruan J, Chen T, Lin E, Shi L (2019) CT-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis. Cancer Imaging 19:82. (PMID: 10.1186/s40644-019-0270-0) Huang DD, Zhou CJ, Wang SL et al (2017) Impact of different sarcopenia stages on the postoperative outcomes after radical gastrectomy for gastric cancer. Surgery 161:680–693. (PMID: 10.1016/j.surg.2016.08.030) Kurk SA, Peeters PHM, Dorresteijn B et al (2018) Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle 9:909–919. (PMID: 10.1002/jcsm.12337) Nishigori T, Tsunoda S, Obama K et al (2018) Optimal cutoff values of skeletal muscle index to define sarcopenia for prediction of survival in patients with advanced gastric cancer. Ann Surg Oncol 25:3596–3603. (PMID: 10.1245/s10434-018-6728-7) Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495. (PMID: 10.1016/S1470-2045(10)70218-7) Aprile G, Basile D, Giaretta R et al (2021) The clinical value of nutritional care before and during active cancer treatment. Nutrients 13:1196. (PMID: 10.3390/nu13041196) Kim N, Yu JI, Park HC et al (2021) Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol Immunother 70:1593–1603. (PMID: 10.1007/s00262-020-02794-3) Akce M, Liu Y, Zakka K et al (2021) Impact of sarcopenia, BMI, and inflammatory biomarkers on survival in advanced hepatocellular carcinoma treated with anti-PD-1 antibody. Am J Clin Oncol 44:74–81. (PMID: 10.1097/COC.0000000000000787) Qayyum A, Bhosale P, Aslam R et al (2021) Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdom Radiol (NY) 46:1008–1015. (PMID: 10.1007/s00261-020-02751-9) Stretch C, Aubin JM, Mickiewicz B et al (2018) Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas. PLoS One 13:e0196235. (PMID: 10.1371/journal.pone.0196235) Lattanzi B, Nardelli S, Pigliacelli A et al (2019) The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease. Dig Liver Dis 51:1508–1512. (PMID: 10.1016/j.dld.2019.09.004) Czigany Z, Kramp W, Bednarsch J et al (2020) Myosteatosis to predict inferior perioperative outcome in patients undergoing orthotopic liver transplantation. Am J Transplant 20:493–503. (PMID: 10.1111/ajt.15577) Hamaguchi Y, Kaido T, Okumura S et al (2019) Preoperative visceral adiposity and muscularity predict poor outcomes after hepatectomy for hepatocellular carcinoma. Liver Cancer 8:92–109. (PMID: 10.1159/000488779) Youn S, Reif R, Chu MP et al (2021) Myosteatosis is prognostic in metastatic melanoma treated with nivolumab. Clin Nutr ESPEN 42:348–353. (PMID: 10.1016/j.clnesp.2021.01.009) VanderVeen BN, Murphy EA, Carson JA (2020) The impact of immune cells on the skeletal muscle microenvironment during cancer cachexia. Front Physiol 11:1037. (PMID: 10.3389/fphys.2020.01037) van Vugt JLA, Coebergh van den Braak RRJ, Schippers HJW et al (2018) Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomography. Clin Nutr 37:1707–1714. (PMID: 10.1016/j.clnu.2017.07.007) |
| معلومات مُعتمدة: | MOST-103-2314-B-002-181-MY2, MOST-105-2314-B-002-194, MOST 106-2314-B-002-213, MOST-108-2314-B-002-072-MY3 Ministry of Science and Technology; MOST-110-2314-B-002-144 Ministry of Science and Technology; MOHW109-TDU-B-211-114002 Ministry of Health and Welfare; NTUH 105S2954, and NTUH 108-S4150 National Taiwan University Hospital |
| فهرسة مساهمة: | Keywords: Hepatocellular carcinoma; Immunotherapy; Myosteatosis; Sarcopenia; Survival |
| تواريخ الأحداث: | Date Created: 20220721 Date Completed: 20221219 Latest Revision: 20221222 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1007/s00330-022-08980-4 |
| PMID: | 35864351 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-1084 |
|---|---|
| DOI: | 10.1007/s00330-022-08980-4 |